Log in to save to my catalogue

PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual...

PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3106895723

PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual disease after neoadjuvant chemotherapy: a cohort study

About this item

Full title

PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual disease after neoadjuvant chemotherapy: a cohort study

Publisher

England: BMJ Publishing Group Ltd and Association of Clinical Pathologists

Journal title

Journal of clinical pathology, 2024-10, Vol.77 (10), p.690-696

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd and Association of Clinical Pathologists

More information

Scope and Contents

Contents

AimsHormone receptor-positive (HR)+/HER2− breast cancer (BC) is highly heterogeneous, with PI3K/PTEN/mTOR pathway alterations emerging as possible players within this complexity. We longitudinally tracked PI3K/PTEN/mTOR pathway dynamics from baseline biopsy to residual disease (RD)—and to metastases in case of relapse—in HR+/HER2− BC patients recei...

Alternative Titles

Full title

PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2− BC patients with residual disease after neoadjuvant chemotherapy: a cohort study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_3106895723

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3106895723

Other Identifiers

ISSN

0021-9746,1472-4146

E-ISSN

1472-4146

DOI

10.1136/jcp-2023-208856

How to access this item